NORADRENALIN
Phase 3Small molecule
NORADRENALIN is one of 40 small molecule programs targeting Oxygenation. It is currently in Phase 3.
2
Indications
5
Total Trials
3
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
53 competitors in Hypotension
#DrugCompanyPhaseTrials
1Levophed
GGeneral Hospital of Ningxia Medical University
Approved
Zofran
NovartisApproved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Ephedrine Sulfate
DDr. Reddys Laboratories, SA
Approved
Proamatine
TakedaApproved
Florinef
Jazz PharmaceuticalsApproved
Intropin
PfizerApproved
Dobutrex
PfizerApproved
Robinul
Jazz PharmaceuticalsApproved
Cardene
Sun Pharmaceutical Industries, Inc.Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Infusion1 trial
Hypotension1 trial
Evaluation of Post-Induction Hypotension Treatment with PRAM Method
Active, not recruiting·—··NCT06787404·100 enrolled
Acute Kidney Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NORADRENALIN. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Aarhus